Physician profile
Daniel Bourque
NPI 1952393084
$4,793.54
in general payments reported to CMS, 2019-2025
30 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $399 · 2021: $734 · 2022: $579 · 2023: $759 · 2024: $777 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.76 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $738.31 | 2019-2025 | Slynd |
| Pfizer INC. | $640.72 | 2019-2025 | |
| Abbvie INC. | $562.69 | 2019-2025 | Orilissa, Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $541.05 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $359.03 | 2023-2025 | Myfembree |
| Takeda Pharmaceuticals U.S.A., INC. | $270.42 | 2020-2025 | Trintellix |
| Avion Pharmaceuticals | $247.50 | 2019-2023 | Balcoltra |
| Therapeuticsmd, INC. | $166.05 | 2019-2022 | |
| Edwards Lifesciences Corporation | $163.49 | 2025 | |
| Mayne Pharma Commercial LLC | $153.97 | 2022-2025 | |
| Millicent US INC | $148.12 | 2021-2025 | Femlyv, Intrarosa, Femring |
| Shield Therapeutics INC | $109.93 | 2023-2025 | Accrufer |
| Duchesnay USA Incorporated | $78.99 | 2019 | |
| Amgen INC. | $77.61 | 2020-2022 | |
| Ethicon US, LLC | $66.46 | 2023-2024 | Stratafix, Vistaseal |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $65.98 | 2019-2024 | Myosure Tissue Removal Device, Omni Hysteroscope |
| Sage Therapeutics, LLC | $59.04 | 2024-2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $55.87 | 2019-2020 | |
| Evofem Biosciences, INC. | $44.38 | 2021-2022 | |
| Dexcom, INC. | $44.16 | 2025 | Dexcom G6 Transmitter |
| Amag Pharmaceuticals, INC. | $32.23 | 2019 | |
| Currax Pharmaceuticals LLC | $28.15 | 2020-2021 | |
| Axsome Therapeutics, INC. | $27.68 | 2025 | Auvelity |
| Scynexis, INC. | $23.92 | 2022 | |
| Allergan, INC. | $17.31 | 2019 | |
| Novo Nordisk INC | $15.77 | 2021 | |
| Shire North American Group INC | $15.71 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.17 | 2020 | |
| Mylan Pharmaceuticals INC. | $13.70 | 2021 | |
| Lupin INC. | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bourque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.